Literature DB >> 13629368

An investigation of ataraxics in labour: meprobamate (equanil).

J J CARROLL, R S MOIR.   

Abstract

Entities:  

Keywords:  LABOR/anesthesia and analgesia; MEPROBAMATE/therapeutic use

Mesh:

Substances:

Year:  1959        PMID: 13629368     DOI: 10.1007/bf03014212

Source DB:  PubMed          Journal:  Can Anaesth Soc J        ISSN: 0008-2856


× No keyword cloud information.
  10 in total

1.  Clinical study of a new tranquilizing drug; use of miltown (2-methyl-2-n-propyl-1,3-propanediol dicarbamate).

Authors:  L S SELLING
Journal:  J Am Med Assoc       Date:  1955-04-30

2.  Use of promethazine (phenergan) hydrochloride in obstetrics; report of a two and one-half year survey.

Authors:  J J CARROLL; R S MOIR
Journal:  J Am Med Assoc       Date:  1958-12-27

3.  Preliminary report on the use of meprobamate for pre-anesthetic sedation.

Authors:  E L RUSHIA
Journal:  J Med Assoc Ga       Date:  1957-03

4.  Meprobamate; its pharmacologic properties and clinical uses.

Authors:  F M BERGER
Journal:  Int Rec Med Gen Pract Clin       Date:  1956-04

5.  POTENTIAL hazards of meprobamate.

Authors: 
Journal:  J Am Med Assoc       Date:  1957-07-20

6.  Meprobamate as adjuvant therapy in hypertension: a preliminary report.

Authors:  R A DUNSMORE; L D DUNSMORE; A F BICKFORD; A GOLDMAN
Journal:  Am J Med Sci       Date:  1957-03       Impact factor: 2.378

7.  NEW AND nonofficial remedies.

Authors: 
Journal:  J Am Med Assoc       Date:  1956-04-21

8.  A clinical study of Miltown, a new tranquilizing agent.

Authors:  L S SELLING
Journal:  J Clin Exp Psychopathol       Date:  1956 Jan-Mar

9.  Meprobamate (equanil) for relief of anxiety and nervous tension from various causes.

Authors:  S E TURVEY
Journal:  Can Med Assoc J       Date:  1956-06-01       Impact factor: 8.262

10.  The pharmacological properties of 2-methyl-2-n-propyl-1,3-propanediol dicarbamate (miltown), a new interneuronal blocking agent.

Authors:  F M BERGER
Journal:  J Pharmacol Exp Ther       Date:  1954-12       Impact factor: 4.030

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.